Verrica Pharmaceuticals (VRCA)
Commercializes YCANTH for molluscum while developing additional dermatology treatments.
$4.72
vs last close+0.23 (+5.12%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 27.66% | 4.75M shares | |
|---|---|---|---|
| 44 holders · as of Jun 30, 2026 | |||
| Insiders | 50.06% | 8.60M shares | |
| 12 holders · as of Aug 18, 2026 | |||
| Other | 22.28% | 3.83M shares | |
| remainder | |||
17.18M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
44 holders · 4.75M shares · 9 new positions · 16 increased · 12 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Caligan Partners LP | 923.9K | 5.38% | 0 | Aug 14, 2026 |
| Cannell Capital LLC | 783.9K | 4.56% | +98.8K | Aug 18, 2026 |
| Affinity Asset Advisors, LLC | 707.3K | 4.12% | 0 | Aug 13, 2026 |
| Velan Capital Investment Management LP | 471.6K | 2.75% | 0 | Aug 14, 2026 |
| Armistice Capital, LLC | 426.3K | 2.48% | −91.9K | Aug 14, 2026 |
| Boothbay Fund Management, LLC | 280.7K | 1.63% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 279.3K | 1.63% | +90.6K | Aug 13, 2026 |
| Mariner, LLC | 207.2K | 1.21% | +182.7K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Paul B Manningincl. BKB Growth Investments, LLC, PBM Capital Investments, LLC | 49.90% | 8.06M | 13D | Nov 28, 2025 |
| Caligan Partners LPincl. David Johnson | 9.99% | 6.50M | 13D | Dec 30, 2025 |
| Armistice Capital, LLC | 9.99% | 9.24M | 13G | Aug 14, 2025 |
| Affinity Asset Advisors, LLC | 5.50% | 884.2K | 13G | Jan 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | John J. Kirbyofficer: Interim CFO | Purchase | 5,000 | $4.93 | 23,962 |
| Aug 18, 2026 | Noah L. Rosenbergofficer: CMO | Purchase | 2,030 | $4.92 | 8,587 |
| Aug 17, 2026 | Noah L. Rosenbergofficer: CMO | Purchase | 4,200 | $4.91 | 6,557 |
| Aug 17, 2026 | Jayson Riegerdirector, officer: CEO and President | Purchase | 5,000 | $4.91 | 207,593 |
| Aug 14, 2026 | Jayson Riegerdirector, officer: CEO and President | Purchase | 20,000 | $5.06 | 202,593 |
| Aug 17, 2026 | David Zawitzofficer: Chief Operating Officer | Purchase | 6,000 | $4.98 | 27,000 |
| Nov 25, 2025 | Paul B. Manningdirector, 10 percent owner: | Purchase · 4 lots | 5,157,677 | $4.66 | 8,338,096 |
| Nov 25, 2025 | Jayson Riegerdirector, officer: CEO and President | Purchase · 2 lots | 117,888 | $4.66 | 206,170 |
| Nov 25, 2025 | David Zawitzofficer: Chief Operating Officer | Purchase · 2 lots | 12,500 | $4.66 | 23,500 |
| Nov 25, 2025 | John J. Kirbyofficer: Interim CFO | Purchase · 2 lots | 4,420 | $4.66 | 9,846 |
House and Senate disclosures
Not reported.